Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.
Nearly half (46.7%) of US adults have hypertension, defined as equal to or greater than 130/80 mm Hg and documented as the leading preventable risk factor for cardiovascular disease (CVD). Hypertension is also a major contributor to kidney disease, complications of pregnancy and childbirth, cognitive decline, and dementia, according to authors of a new joint guideline from the American Heart Association (AHA) and the American College of Cardiology (ACC).1
To mitigate the many downstream outcomes associated with elevated blood pressure, the updated AHA/ACC guideline emphasizes the need for earlier targeted treatment to reduce risk, with a focus on lifestyle modification, pharmacotherapy as necessary but for all levels of hypertension, and use of appropriate therapies for concomitant disease.1
Currently hypertension is more prevalent among men (50.8%) than among women (44.6%). Prevalence increases with age, reaching a rate of 71.6% among adults aged 60 years and older, according to the CDC.2
Unfortunately CDC data reveal that just two-thirds (68.3%) of treated patients are controlled to less than 140/90 mm Hg and only one-fifth have reached the guideline recommended target of less than 130/80 mm Hg.2
The “2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults,” published August 14 in Circulation, Hypertension, and JACC, revises and updates the iteration published in 2017, incorporating updated evidence for use of newer therapies, including GLP-1 receptor agonists, the role early hypertension treatment to reduce the risk of cognitive decline, and incorporating the AHA’s PREVENT (Predicting Risk of cardiovascular disease EVENTs) risk calculator to estimate CVD risk.
“High blood pressure is the most common and most modifiable risk factor for heart disease,” Daniel W. Jones, MD, chair of the writing committee and dean and professor emeritus at the University of Mississippi School of Medicine, said in an AHA statement. “By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure and reduce the toll of heart disease, kidney disease, type 2 diabetes and dementia.”
The guideline continues to recommend the AHA's Life’s Essential 8 behaviors as first-line care for all adults:
The recommended guidance for initiating therapy remains unchanged from the 2017 guideline: For individuals with BP of 140/90 mm Hg or higher (stage 2 hypertension), treatment should begin with 2 medications, ideally in a single combination pill. First-line agents include ACE inhibitors, ARBs, long-acting dihydropyridine calcium channel blockers, and thiazide-type diuretics. Individualizing therapy for patients with comorbidities could include consideration of adding GLP-1 medications in select individuals with hypertension and overweight or obesity.
“This updated guideline is designed to support health care professionals—from primary care teams to specialists—with the diagnosis and care of people with high blood pressure,” Jones said. “It also empowers patients with practical tools that can support their individual health needs as they manage their blood pressure, whether through lifestyle changes, medications or both.”
Eleven other professional societies, including the American Academy of Physician Associates, the American Association of Nurse Practitioners, the American College of Clinical Pharmacy, the American College of Preventive Medicine, the American Geriatrics Society, the American Medical Association, the American Society of Preventive Cardiology, co-endorsed the document.